[go: up one dir, main page]

MX2018009558A - Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfon il-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-m etilbenzoil)guanidina. - Google Patents

Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfon il-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-m etilbenzoil)guanidina.

Info

Publication number
MX2018009558A
MX2018009558A MX2018009558A MX2018009558A MX2018009558A MX 2018009558 A MX2018009558 A MX 2018009558A MX 2018009558 A MX2018009558 A MX 2018009558A MX 2018009558 A MX2018009558 A MX 2018009558A MX 2018009558 A MX2018009558 A MX 2018009558A
Authority
MX
Mexico
Prior art keywords
guanidine
methylbenzoil
etilbenzoil
bismetansulfonil
bismetansulfon
Prior art date
Application number
MX2018009558A
Other languages
English (en)
Other versions
MX391727B (es
Inventor
Saal Christoph
Becker Axel
Kuehn Clemens
Gallon Gilmary
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2018009558A publication Critical patent/MX2018009558A/es
Publication of MX391727B publication Critical patent/MX391727B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/06—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con nuevas modificaciones cristalinas de clorhidrato de N-(4,5-bismetansulfonil-2-metilbenzo il)guanidina, nuevas sales de N-(4,5-bismetansulfonil-2-metilbenzo il)guanidina y sus modificaciones cristalinas y procesos de manufactura y sus formulaciones farmacéuticas.
MX2018009558A 2016-02-08 2017-01-27 Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfonil-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-metilbenzoil)guanidina. MX391727B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16154672 2016-02-08
PCT/EP2017/000102 WO2017137147A1 (en) 2016-02-08 2017-01-27 Crystalline modifications of n-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine hydrochloride and n-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine salts

Publications (2)

Publication Number Publication Date
MX2018009558A true MX2018009558A (es) 2018-09-06
MX391727B MX391727B (es) 2025-03-21

Family

ID=55349673

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009558A MX391727B (es) 2016-02-08 2017-01-27 Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfonil-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-metilbenzoil)guanidina.
MX2021010016A MX2021010016A (es) 2016-02-08 2018-08-06 Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfon il-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-m etilbenzoil)guanidina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021010016A MX2021010016A (es) 2016-02-08 2018-08-06 Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfon il-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-m etilbenzoil)guanidina.

Country Status (10)

Country Link
US (1) US10981864B2 (es)
EP (2) EP4289420A3 (es)
JP (1) JP7050005B2 (es)
CN (2) CN117304079A (es)
AU (1) AU2017217728B2 (es)
CA (2) CA3228796A1 (es)
ES (1) ES2970232T3 (es)
MX (2) MX391727B (es)
RU (1) RU2018131500A (es)
WO (1) WO2017137147A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021552844A1 (en) * 2019-05-24 2022-10-17 Integrative Res Laboratories Sweden Ab Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529612A1 (de) * 1995-08-11 1997-02-13 Merck Patent Gmbh Sulfonyl- oder Sulfinyl-benzoylguanidin-Derivate
DE19951418A1 (de) * 1999-10-26 2001-05-03 Merck Patent Gmbh Verfahren zur Herstellung von N-(4,5-Bismethansulfonyl-2-methyl-benzoyl) -guanidin, Hydrochlorid
DE10023405A1 (de) * 2000-05-12 2001-11-15 Merck Patent Gmbh Verfahren zur Herstellung von Sulfonyl-benzoylguanidinum-Salzen
AU2009243749B2 (en) * 2008-05-09 2013-11-21 Merck Patent Gmbh Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and beta-cell dysfunction

Also Published As

Publication number Publication date
EP3414225B1 (en) 2023-10-25
RU2018131500A (ru) 2020-03-10
EP3414225A1 (en) 2018-12-19
EP3414225C0 (en) 2023-10-25
WO2017137147A1 (en) 2017-08-17
CN117304079A (zh) 2023-12-29
MX2021010016A (es) 2021-09-14
AU2017217728B2 (en) 2021-05-20
JP7050005B2 (ja) 2022-04-07
RU2018131500A3 (es) 2020-07-30
ES2970232T3 (es) 2024-05-27
EP4289420A3 (en) 2024-05-15
CA3013648A1 (en) 2017-08-17
US10981864B2 (en) 2021-04-20
CA3228796A1 (en) 2017-08-17
EP4289420A2 (en) 2023-12-13
US20190345100A1 (en) 2019-11-14
JP2019506455A (ja) 2019-03-07
CA3013648C (en) 2024-03-19
MX391727B (es) 2025-03-21
AU2017217728A1 (en) 2018-09-13
CN108602767A (zh) 2018-09-28

Similar Documents

Publication Publication Date Title
HUE050369T2 (hu) N - ((1,2,3,5,6,7-hexahidro-S-indacen-4-il) -karbamoil)-1-izopropil-1H-pirazol-3-szulfonamid nátrium-sója
CO2019002596A2 (es) Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino
AR100818A1 (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
MX2018005925A (es) Purinonas como inhibidores de proteasa específica de ubiquitina 1.
MA45937A (fr) Inhibiteurs d'amino pyrimidine ssao
AR111469A1 (es) Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
MX2019001376A (es) Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados.
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
UY35275A (es) Derivados de aminopirazina
MX2018014298A (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida.
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
CL2021000903A1 (es) Nhibidores de ror gamma (solicitud divisional de la solicitud 217-2020
UY37647A (es) Amidas de ácido n–(1,3,4–oxadiazol–2–il)arilcarboxílico sustituidas y su compuesto como herbicidas
BR112017004000A2 (pt) formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida
CY1123877T1 (el) Μορφες στερεας καταστασης αλατων νιλοτινιμπης
HUE062726T2 (hu) 1-(1,2-dimetilpropil)-N-etil-5-metil-N-piridazin-4-il-pirazol-4-karboxamid kristályos formái
CO2020001471A2 (es) Compuesto pentacíclico
CL2020000190A1 (es) Inhibidores de ror-gamma.
MX2018016387A (es) Sales cristalinas de inhibidor de inmunoproteasoma de peptido epoxicetona.
MX2018009558A (es) Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfon il-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-m etilbenzoil)guanidina.
BR112018075823A2 (pt) sais farmacêuticos de n-(2-(2-(dimetilamino)etoxi)-4-metoxi-5-((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilamida e suas formas cristalinas
DOP2016000325A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
FR3056331B1 (fr) Polarisation de la region de substrat d'un transistor mos
HUE046959T2 (hu) Eljárás N-(3,5-dimetilfenil)-N'-(2-trifluormetilfenil) guanidin elõállítására
IT201900020976A1 (it) Inibitori del Toll Like Receptor 4 come anti-trombotici